A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma (meso-CART)
An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Vascular Interventional Therapy Mediated Mesothelin-targeted Chimeric Antigen Receptor T Cells in Advanced Pancreatic Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Xu Aimin, Dctor
- Phone Number: 86-13918183196
- Email: xuarmy@163.com
Study Contact Backup
- Name: Yu Xuejun, Master
- Phone Number: 86-18616108610
- Email: yuxuejun@genechem.com.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Recruiting
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Contact:
- Yu Xuejun, Master
- Phone Number: 86-18616108610
- Email: yuxuejun@genechem.com.cn
-
Contact:
- Xu Aimin, Doctor
- Phone Number: 86-13918183196
- Email: xuarmy@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Mesothelin expression positive and histologically confirmed as pancreatic carcinoma;
- Aged between 18 and 69;
- Persistent cancer after at least one prior standard of care chemotherapy, has no willing for surgery or cannot be suitable for surgery patients with or without liver, lymph node metastasis;
- Tumor is too big to surgical resection;
- Life expectancy greater than 4 months;
- Satisfactory organ and bone marrow function as defined by the following: (1) creatinine <1.5mg/dl; (2) albumin >2; (3) cardiac ejection fraction of >55%; (4) ALT/AST<3×the institution normal upper limit; (5) hemoglobin>9g/dl, bilirubin 2.0×the institution normal upper limit; (6) absolute neutrophil count >1,000/ul, platelets>75,000/ul;
- Without bleeding disorder or coagulation disorders;
- Don't allergy to radiocontrast agent;
- Birth control;
- Adequate venous access for apheresis, and no other contraindications for leukapheresis;
- Voluntary informed consent is given.
Exclusion Criteria:
- Pregnant or lactating women;
- Uncontrolled active infection;
- Active hepatitis B or hepatitis C infection;
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary;
- Previously treatment with any gene therapy products;
- Feasibility assessment during screening demonstrates<30% transduction of target lymphocytes, or insufficient expansion (<5-fold) in response to CD3/CD28 costimulation;
- Any serious, uncontrolled diseases (including, but not limit to, unstable angina pectoris, congestive heart failure, grade III or IV cardiac disease, serious arrhythmia, liver and kidney disorders or metabolic diseases, CNS diseases).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TAI-meso-CART
A single dose of meso-CART cells will be administered by vascular interventional mediated as one dose infusions.
The dose is 1-10x106/kg meso-CAR positive T cells.
The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures.
Patients will undergo cannula--DSA radiography--CAR-T cells perfusion.
The cells perfusion process would lasts 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
|
TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with adverse event
Time Frame: 6 weeks
|
asverse event is evaluated with CTCAE, version 4.0
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with tumor response
Time Frame: 8 weeks
|
summarize tumor response by overal response rates
|
8 weeks
|
|
Detection of transferred T cells in the circulation using quantitative -PCR
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Xu Aimin, Doctor, Renji Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Genechem meso-CART
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.